Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

GW Pharma Publishes More Positive Data for Cannabis Drug

By Ryan Bushey | September 27, 2016

GW Pharmaceuticals continued its streak of good luck.

The London-based drug maker posted another set of positive phase 3 data for Epidiolex, an experimental cannabis drug being used to treat seizures in a rare form of epilepsy called Lennox-Gaustaut Syndrome (LGS).

Different doses yielded different results, according to GW’s announcement. A 20-mg dosage of the drug taken daily contributed to a 42 percent drop in monthly seizures compared to 17 percent for participants taking placebo. Volunteers taking 10mg a day experienced an estimated 37 percent monthly drop in seizures while the placebo portion of this group stayed at 17 percent.

Common adverse events varied between diarrhea and upper respiratory infections, but the pattern remained consistent with previous trials. Overall, the drug was generally well tolerated.

This new data bodes well for GW, reported Reuters.

A trove of positive data like this could help the 18-year-old firm support its case for regulatory approval potentially making Epidiolex the first U.S. approved prescription drug extracted from cannabis.

The U.S. Food and Drug Administration has already granted Epidiolex an orphan drug designation for LGS and a similar disorder called Dravet syndrome giving GW a formidable therapeutic candidate in a market that is just starting to develop.

A marketing application is expected to be submitted to the FDA in the first half of next year.


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE